RESUMEN

Human transmembrane adenylyl cyclase 9 (AC9) is not regulated by heterotrimeric G proteins. Key to the resistance to stimulation by Gs-coupled receptors (GsRs) is auto-inhibition by the COOH-terminal domain (C2b). The present study investigated the role of the C2b domain in the regulation of cyclic AMP production by AC9 in HEK293FT cells expressing the GloSensor22F cyclic AMP-reporter protein. Surprisingly, we found C2b to be essential for sustaining the basal output of cyclic AMP by AC9. A human mutation (E326D) in the parallel coiled-coil formed by the signalling helices of AC9 dramatically increased basal activity, which was also dependent on the C2b domain. Intriguingly, the same mutation enabled stimulation of AC9 by GsRs. In summary, auto-regulation by the C2b domain of AC9 sustains its basal activity and quenches activation by GsR. Thus, AC9 appears to be tailored to support constitutive activation of cyclic AMP effector systems. A switch from this paradigm to stimulation by GsRs may be occasioned by conformational changes at the coiled-coil or removal of the C2b domain.

Asunto(s)

Adenilil Ciclasas , AMP Cíclico , Humanos , Adenilil Ciclasas/genética , Adenilil Ciclasas/metabolismo , AMP Cíclico/metabolismo , Mutación , Isoformas de Proteínas/genética , Transducción de Señal

RESUMEN

Dysfunction in the hippocampus-prefrontal cortex (H-PFC) circuit is a critical determinant of schizophrenia. Screening of pyridazinone-risperidone hybrids on this circuit revealed EGIS 11150 (S 36549). EGIS 11150 induced theta rhythm in hippocampal slice preparations in the stratum lacunosum molecular area of CA1, which was resistant to atropine and prazosin. EGIS 11150 enhanced H-PFC coherence, and increased the 8−9 Hz theta band of the EEG power spectrum (from 0.002 mg/kg i.p, at >30× lower doses than clozapine, and >100× for olanzapine, risperidone, or haloperidol). EGIS 11150 fully blocked the effects of phencyclidine (PCP) or ketamine on EEG. Inhibition of long-term potentiation (LTP) in H-PFC was blocked by platform stress, but was fully restored by EGIS 11150 (0.01 mg/kg i.p.), whereas clozapine (0.3 mg/kg ip) only partially restored LTP. EGIS 11150 has a unique electrophysiological profile, so phenotypical screening on H-PFC connectivity can reveal novel antipsychotics.

Asunto(s)

Antipsicóticos , Clozapina , Animales , Antipsicóticos/farmacología , Clozapina/farmacología , Hipocampo , Plasticidad Neuronal , Corteza Prefrontal , Ratas , Ratas Wistar , Risperidona/farmacología

RESUMEN

Obesity and diabetes mellitus have become the surprising menaces of relative economic well-being worldwide. Gamma amino butyric acid (GABA) has a prominent role in the control of blood glucose, energy homeostasis as well as food intake at several levels of regulation. The effects of GABA in the body are exerted through ionotropic GABAA and metabotropic GABAB receptors. This treatise will focus on the pharmacologic targeting of GABAA receptors to reap beneficial therapeutic effects in diabetes mellitus and obesity. A new crop of drugs selectively targeting GABAA receptors has been under investigation for efficacy in stroke recovery and cognitive deficits associated with schizophrenia. Although these trials have produced mixed outcomes the compounds are safe to use in humans. Preclinical evidence is summarized here to support the rationale of testing some of these compounds in diabetic patients receiving insulin in order to achieve better control of blood glucose levels and to combat the decline of cognitive performance. Potential therapeutic benefits could be achieved (i) By resetting the hypoglycemic counter-regulatory response; (ii) Through trophic actions on pancreatic islets, (iii) By the mobilization of antioxidant defence mechanisms in the brain. Furthermore, preclinical proof-of-concept work, as well as clinical trials that apply the novel GABAA compounds in eating disorders, e.g., olanzapine-induced weight-gain, also appear warranted.

RESUMEN

A recent break-through paper has revealed for the first time the high-resolution, three-dimensional structure of a mammalian trans-membrane adenylyl cyclase (tmAC) obtained by cryo-electronmicroscopy (cryo-EM). Reporting the structure of adenylyl cyclase 9 (AC9) in complex with activated Gsα, the cryo-EM study revealed that AC9 has three functionally interlinked, yet structurally distinct domains. The array of the twelve transmembrane helices is connected to the cytosolic catalytic core by two helical segments that are stabilized through the formation of a parallel coiled-coil. Surprisingly, in the presence of Gsα, the isoform-specific carboxyl-terminal tail of AC9 occludes the forskolin- as well as the active substrate-sites, resulting in marked autoinhibition of the enzyme. As AC9 has the lowest primary sequence homology with the eight further mammalian tmAC paralogues, it appears to be the best candidate for selective pharmacologic targeting. This is now closer to reality as the structural insight provided by the cryo-EM study indicates that all of the three structural domains are potential targets for bioactive agents. The present paper summarizes for molecular physiologists and pharmacologists what is known about the biological role of AC9, considers the potential modes of physiologic regulation, as well as pharmacologic targeting on the basis of the high-resolution cryo-EM structure. The translational potential of AC9 is considered upon highlighting the current state of genome-wide association screens, and the corresponding experimental evidence. Overall, whilst the high- resolution structure presents unique opportunities for the full understanding of the control of AC9, the data on the biological role of the enzyme and its translational potential are far from complete, and require extensive further study.

Asunto(s)

Adenilil Ciclasas , Adenilil Ciclasas/química , Adenilil Ciclasas/fisiología , Animales , Línea Celular , Estudio de Asociación del Genoma Completo , Humanos , Conformación Proteica , Dominios Proteicos

RESUMEN

It is now widely accepted that magnocellular vasopressinergic neurons in the supraoptic and paraventricular nuclei participate in the control of adrenocorticotropin secretion by the anterior pituitary gland. However, it remains to be explored in further detail, when and how these multifunctional neurons are involved in the control of anterior pituitary function. This paper highlights the role of magnocellular vasopressin in the hypothalamic pituitary adrenocortical axis with special reference to escape from glucocorticoid feedback inhibition. The signaling mechanisms underlying glucocorticoid escape by pituitary corticotrope cells, as well as the wider physiologic and pathologic contexts in which escape is known to occur-namely strenuous exercise, and autoimmune inflammation will be considered. It is proposed that by inducing escape from glucocorticoid feedback inhibition at the pituitary level, magnocellular vasopressin is critically important for the anti-inflammatory, and immunosuppressant actions of endogenous corticosteroids.

RESUMEN

In mammals, nine genes encode trans-membrane adenylyl cyclase (tmAC) isoforms that synthesize the intracellular messenger compound cAMP from ATP. As cAMP is produced in virtually all types of cell, isoform-selective modulators of tmAC would have major research and therapeutic potential. This study investigated the effects of fungicide imidazoles previously shown to suppress cAMP production in various tissues on the activities of tmAC isoforms AC1, 2, or 9 stably expressed in human embryonic kidney 293 cells. Intact cells, as well as crude membranes, were exposed to various imidazoles or known stimulators of tmAC and the ensuing changes in the production of cAMP analyzed. In crude membranes, the activity of AC9 in the presence of GDP-ß-S was enhanced by miconazole with an EC50 of ~ 8 µM, while AC1 and AC2 were inhibited with an IC50 of ~ 20 µM. Clotrimazole (10-100 µM) was an inhibitor of all the ACs tested. Substrate saturation analysis indicated that miconazole increased the Vmax of AC9 by 3-fold while having no effect on the Km. In intact cells, the effect of miconazole on cAMP production through AC9 was additive with that of isoproterenol. The stimulation of cAMP production by miconazole was inhibited by Ca2+, and this could be prevented by the calcineurin blocker FK506. In sum, activation of AC9 by miconazole is through a mechanism distinct from that of forskolin, activated G proteins, or the COOH-terminal mediated autoinhibition. However, it is subject to the AC9 isoform-specific inhibition by Ca2+/calcineurin. Differential modulation of mammalian tmAC paralogs appears to be achievable by an imidazole with phenylated side chains. Optimization of the lead compound and exploration of the underlying mechanism(s) of action in more detail could exploit this further.

Asunto(s)

Adenilil Ciclasas/metabolismo , Fungicidas Industriales/farmacología , Imidazoles/farmacología , Adenilil Ciclasas/genética , AMP Cíclico/metabolismo , Células HEK293 , Humanos

RESUMEN

Trans-membrane adenylyl cyclase (tmAC) isoforms show markedly distinct regulatory properties that have not been fully explored. AC9 is highly expressed in vital organs such as the heart and the brain. Here, we report that the isoform-specific carboxyl-terminal domain (C2b) of AC9 inhibits the activation of the enzyme by Gs-coupled receptors (GsCR). In human embryonic kidney cells (HEK293) stably overexpressing AC9, cAMP production by AC9 induced upon the activation of endogenous ß-adrenergic and prostanoid GsCRs was barely discernible. Cells expressing AC9 lacking the C2b domain showed a markedly enhanced cAMP response to GsCR. Subsequent studies of the response of AC9 mutants to the activation of GsCR revealed that residues 1268-1276 in the C2b domain were critical for auto-inhibition. Two main species of AC9 of 130 K and ≥ 170 K apparent molecular weight were observed on immunoblots of rodent and human myocardial membranes with NH2-terminally directed anti-AC9 antibodies. The lower molecular weight AC9 band did not react with antibodies directed against the C2b domain. It was the predominant species of AC9 in rodent heart tissue and some of the human samples. There is a single gene for AC9 in vertebrates, moreover, amino acids 957-1353 of the COOH-terminus are encoded by a single exon with no apparent signs of mRNA splicing or editing making it highly unlikely that COOH-terminally truncated AC9 could arise through the processing or editing of mRNA. Thus, deductive reasoning leads to the suggestion that proteolytic cleavage of the C2b auto-inhibitory domain may govern the activation of AC9 by GsCR.

Asunto(s)

Adenilil Ciclasas/metabolismo , Membrana Celular/metabolismo , Giro del Cíngulo/metabolismo , Hipocampo/metabolismo , Miocardio/metabolismo , Miocitos Cardíacos/metabolismo , Adenilil Ciclasas/genética , Animales , AMP Cíclico/metabolismo , Células HEK293 , Ventrículos Cardíacos/metabolismo , Humanos , Isoenzimas/genética , Isoenzimas/metabolismo , Masculino , Proteínas de la Membrana/genética , Proteínas de la Membrana/metabolismo , Ratones , Ratones Endogámicos C57BL , Mutación , Dominios Proteicos , Receptores Acoplados a Proteínas G/metabolismo , Transducción de Señal

RESUMEN

This study examined the potential of the selective extra-synaptic α5-GABAA receptor inhibitor S44819 (Egis-13529) to improve cognitive performance in preclinical models of vascular cognitive impairment (VCI). Chronic hypoperfusion of the brain in mice was induced by permanent occlusion of the right common carotid artery (rUCO). rUCO induced impairments of cognitive function in the object recognition test (OR) and the rewarded T-maze (RTM). In both tests, a single oral treatment with S44819 (OR - 0.1-3 mg/kg, RTM - 1-3 mg/kg p.o.) significantly reduced the effect of rUCO. Long-term treatment with S44819 (1-10 mg/kg twice daily p.o. for 14 days), that was initiated 24 h after surgery and was followed by a 10- or 13-day wash-out period, fully prevented the decline of cognitive performance of rUCO mice. In rats, occlusion of the middle cerebral artery (MCA) for 30 min caused a significantly diminished performance in the OR. This was prevented by S44819 given p.o. 15 mg/kg twice daily for 8 days, starting 7 days after surgery and tested following a 7-day wash-out period. Taken together, S44819 markedly and stably improved reference and working memory impaired by rUCO in mice. In rats, the compound effectively suppressed the development of cognitive impairment after mild stroke. In conclusion, as longer-term administration led to a persistent reversal of the cognitive deficits, it appears that S44819 may have symptomatic, as well as disease-modifying effects in models of VCI. Proof of concept is therefore provided for testing S44819 in the therapy of VCI and post-stroke dementia in humans.

Asunto(s)

Benzodiazepinas/farmacología , Demencia Vascular/tratamiento farmacológico , Antagonistas de Receptores de GABA-A/farmacología , Oxazoles/farmacología , Receptores de GABA-A/metabolismo , Animales , Benzodiazepinas/administración & dosificación , Benzodiazepinas/uso terapéutico , Cognición/efectos de los fármacos , Demencia Vascular/metabolismo , Demencia Vascular/fisiopatología , Modelos Animales de Enfermedad , Antagonistas de Receptores de GABA-A/administración & dosificación , Antagonistas de Receptores de GABA-A/uso terapéutico , Masculino , Ratones , Oxazoles/administración & dosificación , Oxazoles/uso terapéutico , Ratas , Reconocimiento en Psicología/efectos de los fármacos , Reconocimiento en Psicología/fisiología

RESUMEN

Gamma-amino butyric acid (GABA) is an abundant neurotransmitter in the CNS. GABAergic interneurons orchestrate pyramidal neurons in the cerebral cortex, and thus control learning and memory. Ionotropic receptors for GABA (GABAAR) are heteropentameric complexes of α, ß and γ integral membrane-protein subunits forming Cl- -channels operated by GABA, which are vital for brain function and are important drug targets. However, knowledge on how GABAAR bind GABA is controversial. Structural biology versus functional modelling combined with site-directed mutagenesis suggest markedly different roles for loop F of the extracellular domain of the α-subunit when complexed with GABA. Here, we report that contrary to the results of structural studies, loop F of the α-subunit controls the potency of GABA on GABAAR. We examined the effect of replacing a short, variable segment of loop F of the GABAA α5-subunit with the corresponding segment of the α2-subunit (GABAA5_LF2) and vice versa (GABAA2-LF5). When compared with their respective wild-type counterparts, GABAA5_LF2 receptors displayed enhanced sensitivity towards GABA, whilst in GABAA2-LF5 sensitivity was diminished. Mice homozygous for the genetic knock-in of the GABAA5_LF2 subunit showed a marked deficit in long- but not short-term object recognition memory. Working memory in place learning, spontaneous alternation and the rewarded T-maze were all normal. The deficit in long-term recognition memory was reversed by an α5-GABAA negative allosteric modulator compound. The data show that loop F governs GABA potency in a receptor isoform-specific manner in vitro. Moreover, this mechanism of ligand recognition appears to be operative in vivo and impacts cognitive performance.

Asunto(s)

Subunidades de Proteína/metabolismo , Receptores de GABA-A/química , Receptores de GABA-A/metabolismo , Ácido gamma-Aminobutírico/metabolismo , Animales , Unión Competitiva , Conducta Exploratoria/fisiología , Células HEK293 , Humanos , Masculino , Aprendizaje por Laberinto/fisiología , Potenciales de la Membrana/efectos de los fármacos , Potenciales de la Membrana/genética , Ratones , Ratones Endogámicos C57BL , Ratones Transgénicos , Mutagénesis Sitio-Dirigida , Mutación/genética , Técnicas de Placa-Clamp , Subunidades de Proteína/genética , Receptores de GABA-A/genética , Reconocimiento en Psicología/fisiología , Relación Estructura-Actividad , Factores de Tiempo , Transfección , Ácido gamma-Aminobutírico/farmacología

RESUMEN

In the mammalian central nervous system (CNS) GABAA receptors (GABAARs) mediate neuronal inhibition and are important therapeutic targets. GABAARs are composed of 5 subunits, drawn from 19 proteins, underpinning expression of 20-30 GABAAR subtypes. In the CNS these isoforms are heterogeneously expressed and exhibit distinct physiological and pharmacological properties. We report the discovery of S44819, a novel tricyclic oxazolo-2,3-benzodiazepine-derivative, that selectively inhibits α5-subunit-containing GABAARs (α5-GABAARs). Current α5-GABAAR inhibitors bind to the "benzodiazepine site". However, in HEK293 cells expressing recombinant α5-GABAARs, S44819 had no effect on 3H-flumazenil binding, but displaced the GABAAR agonist 3H-muscimol and competitively inhibited the GABA-induced responses. Importantly, we reveal that the α5-subunit selectivity is uniquely governed by amino acid residues within the α-subunit F-loop, a region associated with GABA binding. In mouse hippocampal CA1 neurons, S44819 enhanced long-term potentiation (LTP), blocked a tonic current mediated by extrasynaptic α5-GABAARs, but had no effect on synaptic GABAARs. In mouse thalamic neurons, S44819 had no effect on the tonic current mediated by δ-GABAARs, or on synaptic (α1ß2γ2) GABAARs. In rats, S44819 enhanced object recognition memory and reversed scopolamine-induced impairment of working memory in the eight-arm radial maze. In conclusion, S44819 is a first in class compound that uniquely acts as a potent, competitive, selective antagonist of recombinant and native α5-GABAARs. Consequently, S44819 enhances hippocampal synaptic plasticity and exhibits pro-cognitive efficacy. Given this profile, S44819 may improve cognitive function in neurodegenerative disorders and facilitate post-stroke recovery.

Asunto(s)

Benzodiazepinas/farmacología , Antagonistas de Receptores de GABA-A/farmacología , Nootrópicos/farmacología , Oxazoles/farmacología , Receptores de GABA-A/metabolismo , Animales , Unión Competitiva , Encéfalo/efectos de los fármacos , Encéfalo/metabolismo , Femenino , Flumazenil/farmacología , Agonistas de Receptores de GABA-A/farmacología , Células HEK293 , Humanos , Potenciación a Largo Plazo/efectos de los fármacos , Potenciación a Largo Plazo/fisiología , Masculino , Memoria/efectos de los fármacos , Memoria/fisiología , Ratones Endogámicos C57BL , Muscimol/farmacología , Inhibición Neural/efectos de los fármacos , Inhibición Neural/fisiología , Ratas Sprague-Dawley , Técnicas de Cultivo de Tejidos , Ácido gamma-Aminobutírico/farmacología

RESUMEN

Previous work has shown that S44819 is a novel GABAA receptor (GABAAR) antagonist, which is selective for extrasynaptic GABAARs incorporating the α5 subunit (α5-GABAARs). The present study reports on the preclinical neuropsychopharmacological profile of S44819. Significantly, no sedative or pro-convulsive side effects of S44819 were found at doses up to 30 mg/kg i.p. Object recognition (OR) memory in intact mice was enhanced by S44819 (0.3 mg/kg p.o.) given before the acquisition trial. Mice treated with phencyclidine for two weeks and tested six days after the cessation of treatment failed to show OR memory. This deficit was corrected by a single administration of S44819 (0.1, 0.3 or 1 mg/kg p.o.) prior to the acquisition trial. The amnestic effect of ketamine in rats tested in the eight-arm radial maze (reference and working memory versions) was blocked by S44819 (3 mg/kg p.o.). Extinction of cued fear was preserved during treatment with S44819 (3 mg/kg/diem i.p.). Administration of S44819 had no significant effect in the Vogel-conflict test, the elevated plus maze, the forced swim, the marble-burying and the tail-suspension tests. In contrast, anxiolytic/antidepressant-like effects of the compound were found in paradigms that have mnemonic components, such as social interaction, fear-potentiated startle and social avoidance induced by negative life experience. In summary, S44819 enhanced intact recognition memory and ameliorated memory deficits induced by inhibition of NMDA receptors. Anxiolytic/antidepressant efficacy was limited to paradigms involving cognitive function. In conclusion, S44819 is a novel psychoactive pro-cognitive compound with potential as a therapeutic agent in dementia.

Asunto(s)

Benzodiazepinas/farmacología , Antagonistas de Receptores de GABA-A/farmacología , Trastornos de la Memoria/tratamiento farmacológico , Memoria/efectos de los fármacos , Nootrópicos/farmacología , Oxazoles/farmacología , Animales , Ansiolíticos/farmacología , Antidepresivos/farmacología , Cognición/efectos de los fármacos , Cognición/fisiología , Relación Dosis-Respuesta a Droga , Evaluación Preclínica de Medicamentos , Miedo/efectos de los fármacos , Miedo/fisiología , Ketamina , Aprendizaje/efectos de los fármacos , Aprendizaje/fisiología , Masculino , Memoria/fisiología , Trastornos de la Memoria/metabolismo , Ratones , Fenciclidina , Ratas , Receptores de GABA-A/metabolismo , Receptores de N-Metil-D-Aspartato/antagonistas & inhibidores , Receptores de N-Metil-D-Aspartato/metabolismo , Conducta Social

RESUMEN

The neurotransmitter γ-amino butyric acid (GABA) has a fundamental role in CNS function and ionotropic (GABAA) receptors that mediate many of the actions of GABA are important therapeutic targets. This study reports the mechanism of action of novel GABAA antagonists based on a tricyclic oxazolo-2,3-benzodiazepine scaffold. These compounds are orthosteric antagonists of GABA on heteropentameric GABAA receptors of αxß2γ2 configuration expressed in HEK293 cells. In silico modelling predicted that the test compounds docked in the GABA binding-pocket and would interact with amino-acid residues in the α- and ß-subunit interface that are known to be important for the binding of GABA. Intriguingly, optimal docking also required an interaction with the non-conserved amino-terminal segment of Loop-F of the α-subunit. Testing of a compound with altered regiochemistry of the oxazolone moiety supported the model with respect to the conserved GABA-interacting residues in vitro as well as in vivo. The prediction regarding loop-F was examined by replacing the amino-terminal variable segment of loop-F of the α5-subunit with the corresponding residues in the α1- and α2-subunits. When tested with the novel inhibitors, the receptors formed by the modified α5-subunits displayed the pharmacologic phenotype of the source of loop-F. In summary, these data show that the variable amino-terminal segment of loop-F of the α-subunit determines the pharmacologic selectivity of the novel tricyclic inhibitors of GABAA receptors.

Asunto(s)

Benzodiazepinas/química , Benzodiazepinas/farmacología , Antagonistas de Receptores de GABA-A/química , Antagonistas de Receptores de GABA-A/farmacología , Subunidades de Proteína/metabolismo , Receptores de GABA-A/química , Receptores de GABA-A/metabolismo , Benzodiazepinas/metabolismo , Unión Competitiva , Simulación por Computador , Antagonistas de Receptores de GABA-A/metabolismo , Células HEK293 , Humanos , Simulación del Acoplamiento Molecular , Oxazoles/química , Conformación Proteica , Subunidades de Proteína/química , Relación Estructura-Actividad , Ácido gamma-Aminobutírico/metabolismo

RESUMEN

Novel 2,3-benzodiazepine and related isoquinoline derivatives, substituted at position 1 with a 2-benzothiophenyl moiety, were synthesized to produce compounds that potently inhibited the action of GABA on heterologously expressed GABAA receptors containing the alpha 5 subunit (GABAA α5), with no apparent affinity for the benzodiazepine site. Substitutions of the benzothiophene moiety at position 4 led to compounds with drug-like properties that were putative inhibitors of extra-synaptic GABAA α5 receptors and had substantial blood-brain barrier permeability. Initial characterization in vivo showed that 8-methyl-5-[4-(trifluoromethyl)-1-benzothiophen-2-yl]-1,9-dihydro-2H-[1,3]oxazolo[4,5-h][2,3]benzodiazepin-2-one was devoid of sedative, pro-convulsive or motor side-effects, and enhanced the performance of rats in the object recognition test. In summary, we have discovered a first-in-class GABA-site inhibitor of extra-synaptic GABAA α5 receptors that has promising drug-like properties and warrants further development.

Asunto(s)

Anticonvulsivantes/farmacología , Benzodiazepinas/farmacología , Antagonistas de Receptores de GABA-A/farmacología , Nootrópicos/farmacología , Receptores de GABA-A/efectos de los fármacos , Animales , Anticonvulsivantes/síntesis química , Anticonvulsivantes/metabolismo , Anticonvulsivantes/toxicidad , Conducta Animal/efectos de los fármacos , Benzodiazepinas/síntesis química , Benzodiazepinas/metabolismo , Benzodiazepinas/toxicidad , Barrera Hematoencefálica/metabolismo , Permeabilidad Capilar , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Antagonistas de Receptores de GABA-A/síntesis química , Antagonistas de Receptores de GABA-A/metabolismo , Antagonistas de Receptores de GABA-A/toxicidad , Células HEK293 , Humanos , Masculino , Ratones , Estructura Molecular , Actividad Motora/efectos de los fármacos , Nootrópicos/síntesis química , Nootrópicos/metabolismo , Nootrópicos/toxicidad , Pentilenotetrazol , Ratas Sprague-Dawley , Receptores de GABA-A/genética , Receptores de GABA-A/metabolismo , Reconocimiento en Psicología/efectos de los fármacos , Convulsiones/inducido químicamente , Convulsiones/prevención & control , Relación Estructura-Actividad , Xenopus laevis

RESUMEN

Optical waveguide lightmode spectroscopic (OWLS) techniques were probed for monitoring ion permeation through channels incorporated into artificial lipid environment. A novel sensor set-up was developed by depositing liposomes or cell-derived membrane fragments onto hydrophilic polytetrafluoroethylene (PTFE) membrane. The fibrous material of PTFE membrane could entrap lipoid vesicles and the water-filled pores provided environment for the hydrophilic domains of lipid-embedded proteins. The sensor surface was kept clean from the lipid holder PTFE membrane by a water- and ion-permeable polyethylene terephthalate (PET) mesh. The sensor set-up was tested with egg yolk lecithin liposomes containing gramicidin ion channels and with cell-derived membrane fragments enriched in GABA-gated anion channels. The method allowed monitoring the move of Na(+) and organic cations through gramicidin channels and detecting the Cl(-)-channel functions of the (α5ß2γ2) GABAA receptor in the presence or absence of GABA and the competitive GABA-blocker bicuculline.

Asunto(s)

Membrana Celular/metabolismo , Canales Iónicos/metabolismo , Rayos Láser , Dispositivos Ópticos , Gramicidina/metabolismo , Células HEK293 , Humanos , Liposomas/metabolismo , Movimiento , Unión Proteica , Receptores de GABA-A/metabolismo

RESUMEN

Classical antipsychotics, e.g. haloperidol, chlorpromazine, are potent at controlling the positive symptoms of schizophrenia but frequently elicit extrapyramidal motor side-effects. The introduction of atypical antipsychotics such as risperidone, olanzapine and clozapine has obviated this problem, but none of the current drugs seem to improve the cognitive deficits accompanying schizophrenia. Thus there is an unmet need for agents that not only suppress the psychotic symptoms but also ameliorate the impairment of cognition. Here, we report the preclinical properties of a candidate antipsychotic, Egis-11150, that shows marked pro-cognitive efficacy. Egis-11150 displayed high affinity for adrenergic α(1), α(2c), 5-HT(2A) 5-HT7, moderate affinity for adrenergic α(2a) and D2 receptors. It was a functional antagonist on all of the above receptors, with the exception of 5-HT7 receptors, where it was an inverse agonist. Phencyclidine-induced hypermotility in mice and inhibition of conditioned avoidance response in rats were assessed to estimate efficacy against the positive and social withdrawal test in rats was used to predict efficacy against the negative symptoms of schizophrenia. Passive-avoidance learning, novel object recognition and radial maze tests in rats were used to assess pro-cognitive activity, while phencyclidine-induced disruption of prepulse inhibition in mice was examined to test for effects on attention. Egis-11150 (0.01-0.3 mg/kg, ip.) was effective in all of the preclinical models of schizophrenia examined. Moreover, a robust pro-cognitive profile was apparent. In summary, work in preclinical models indicates that Egis-11150 is a potential treatment for controlling the psychosis as well as the cognitive dysfunction in schizophrenia. This article is part of a Special Issue entitled 'Cognitive Enhancers'.

Asunto(s)

Antipsicóticos/uso terapéutico , Trastornos del Conocimiento/prevención & control , Drogas en Investigación/uso terapéutico , Nootrópicos/uso terapéutico , Piperidinas/uso terapéutico , Piridazinas/uso terapéutico , Esquizofrenia/tratamiento farmacológico , Antagonistas de Receptores Adrenérgicos alfa 1/administración & dosificación , Antagonistas de Receptores Adrenérgicos alfa 1/efectos adversos , Antagonistas de Receptores Adrenérgicos alfa 1/uso terapéutico , Animales , Antipsicóticos/administración & dosificación , Antipsicóticos/efectos adversos , Conducta Animal/efectos de los fármacos , Trastornos del Conocimiento/etiología , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Drogas en Investigación/administración & dosificación , Drogas en Investigación/efectos adversos , Masculino , Memoria a Corto Plazo/efectos de los fármacos , Ratones , Ratones Endogámicos , Nootrópicos/administración & dosificación , Nootrópicos/efectos adversos , Piperidinas/administración & dosificación , Piperidinas/efectos adversos , Piridazinas/administración & dosificación , Piridazinas/efectos adversos , Distribución Aleatoria , Ratas , Ratas Sprague-Dawley , Ratas Wistar , Esquizofrenia/fisiopatología , Antagonistas del Receptor de Serotonina 5-HT2/administración & dosificación , Antagonistas del Receptor de Serotonina 5-HT2/efectos adversos , Antagonistas del Receptor de Serotonina 5-HT2/uso terapéutico

RESUMEN

The most recently discovered serotonin (5-HT) receptor subtype, 5-HT(7), is considered to be associated with several CNS disorders. Noninvasive in vivo positron emission tomography (PET) studies of cerebral 5-HT(7) receptors could provide a significant advance in the understanding of the neurobiology and eventual dysfunctions of the 5-HT(7) receptor. To date, no appropriate 5-HT(7) receptor PET ligand has been developed. Here, we modified known 5-HT(7) selective phenylpiperazinyl-butyloxindole derivatives so that they may be labeled either with carbon-11 or fluorine-18. A set of potential 5-HT(7) ligands for PET molecular imaging was successfully synthesized. Two compounds (10 and 14) were tested against a range of targets. Both compounds display a promising in vitro profile with respect to PET imaging of the 5-HT(7) receptor in thalamic regions.

Asunto(s)

Encéfalo/diagnóstico por imagen , Piperidinas/síntesis química , Tomografía de Emisión de Positrones/métodos , Radiofármacos/síntesis química , Receptores de Serotonina/metabolismo , Encéfalo/metabolismo

RESUMEN

Calcium ions and cyclic adenosine monophosphate (cAMP) are virtually ubiquitous intracellular signaling molecules in mammalian cells. This paper will focus on the cross-talk between Ca(2+) and cAMP mobilizing signaling pathways and summarize the underlying molecular mechanisms. Subsequently, workings of adenohypophyseal corticotrope cells will be reviewed to highlight the physiological relevance of a Ca(2+) cAMP interactions in neuroendocrinology.

Asunto(s)

Hormona Adrenocorticotrópica/metabolismo , Señalización del Calcio , Calcio/metabolismo , Corticotrofos/fisiología , AMP Cíclico/metabolismo , Animales , Calcio/química , Humanos , Sistemas de Mensajero Secundario/fisiología

RESUMEN

Signalling through adenosine 3'5' monophosphate (cAMP) is known to be important in virtually every cell. The mapping of the human genome over the past two decades has revealed an unexpected complexity of cAMP signalling, which is shared from insects to mammals. A more recent technical advance is the ability to monitor intracellular cAMP levels at subcellular spatial resolution within the time-domains of fast biochemical reactions. Thus, new light has been shed on old paradigms, some of which turn out to be multiple new ones. The novel aspects of cAMP signalling are highlighted here: (1) agonist induced plasticity - showing how the repertory of cAMP signalling genes supports homeostatic adaptation; (2) sustained cAMP signalling after endocytosis; (3) pre-assembled receptor-Gs-adenylyl cyclase complexes. Finally, a hypothetical model of propagating neuronal cAMP signals travelling form dendrites to the cell body is presented.

Asunto(s)

AMP Cíclico/metabolismo , Sistemas de Mensajero Secundario/fisiología , Adenilil Ciclasas/genética , Adenilil Ciclasas/metabolismo , Animales , AMP Cíclico/genética , Dendritas/genética , Dendritas/metabolismo , Proteínas de Unión al GTP/genética , Proteínas de Unión al GTP/metabolismo , Genoma Humano/fisiología , Humanos , Insectos/genética , Insectos/metabolismo , Complejos Multienzimáticos/genética , Complejos Multienzimáticos/metabolismo

RESUMEN

The molecular and cellular basis of the psychotropic actions of adrenal corticosteroids is poorly understood. Previously, we reported that modulation of large conductance Ca2+-activated potassium channel (BK-channel) function by glucocorticoids can be recapitulated in human embryonic kidney293 (HEK293) cells (J Physiol 537:57, 2001). In the present paper, we examined the effect of dexamethasone on the expression of candidate mediator proteins of glucocorticoid action, dex-ras1 and serum and glucocorticoid inducible protein kinase 1 (SGK), in HEK293 cells. Dex-ras1 mRNA was readily detectable under basal conditions however, no changes of dex-ras1 mRNA expression occurred upon exposure to 100 nM of dexamethasone for 2 h. In contrast, a 2.5-fold increase of SGK mRNA was found under similar conditions. Total levels of cellular SGK protein were unaltered upon exposure to dexamethasone, but a marked increase of SGK in a Triton-X100 insoluble fraction was observed. BK-channel alpha-subunits could not be co-immunoprecipitated with SGK. In summary, SGK, but not dex-ras1, mRNA is rapidly induced by glucocorticoid stimulation in HEK293 cells. However, there appears to be no direct protein-protein interaction between SGK and BK-channel alpha-subunits.

Asunto(s)

Dexametasona/farmacología , Proteínas Inmediatas-Precoces/genética , Proteínas Serina-Treonina Quinasas/genética , Proteínas ras/genética , Northern Blotting , Línea Celular Tumoral , Genes Reporteros/efectos de los fármacos , Genes Reporteros/genética , Humanos , Inmunoprecipitación , Luciferasas/genética , Canales de Potasio Calcio-Activados/efectos de los fármacos , ARN Mensajero/biosíntesis , ARN Mensajero/genética , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa

RESUMEN

The intracellular messenger cAMP is essential for vital processes ranging from ovulation to cognition. There are 10 genes for adenylyl cyclase (AC), the biosynthetic enzyme of cAMP. Nine of these encode membrane-bound proteins and one gives rise to soluble AC. The understanding of the biological significance of this molecular diversity is incomplete. Membrane-bound ACs conform to the same structural blueprint but have markedly different regulatory characteristics. AC mRNAs are differentially distributed in the body suggesting non-redundant physiological functions. The subcellular localisation of AC isoforms has not been examined in detail. Here we discuss the current knowledge on the intracellular targeting of AC isoforms, and highlight the technical problems of AC detection, some of which appear to be caused by the poor quality-control of commercially supplied antibodies. The principal message is that intracellular targeting of ACs may be isoform-specific and also dependent on the cellular context of expression.

Asunto(s)

Adenilil Ciclasas/metabolismo , Genoma , Isoenzimas/metabolismo , Adenilil Ciclasas/genética , Secuencia de Aminoácidos , Animales , Línea Celular , Humanos , Inmunohistoquímica , Isoenzimas/genética , Masculino , Datos de Secuencia Molecular , ARN Mensajero/genética , Ratas , Ratas Wistar , Homología de Secuencia de Aminoácido